Finally, we further evaluated the prognostic value and found that the score for the three biomarkers combined was significantly associated with OS (Fig. 4J), and these findings suggest that low expression of ARHGAP35 in combination with high expression of FTO and ALKBH5 may serve as a vital clinical biomarker of poor prognosis in NPC patients. This evidence concerns the gene FTO and nasopharyngeal carcinoma.